BACKGROUND {#sec0005}
==========

There is accumulating evidence that 25-hydroxyvitamin D (25-(OH)D) is not only involved in bone health, but may also play a role in non-skeletal systems via the vitamin D receptor (VDR) \[[@ref001]\]. Vitamin D receptors, and the enzyme that converts 25-hydroxyvitamin D into active vitamin D, are found throughout the brain \[[@ref001]\]. It is also suggested that vitamin D plays a role in brain development and in neurodegenerative diseases as Parkinson's disease (PD) and dementia \[[@ref001]\]; however, this relationship is not well understood.

Vitamin D can be ingested or synthesized in the human skin as the pre-vitamin D, (25-(OH)D). Thereafter, 25-(OH)D has to be hydroxylated twice to become the active form 1,25-dihydroxyvitamin D (1,25-(OH)~2~D); these hydroxylations occur first in the liver and then in the kidney. 1,25-(OH)~2~D binds to the VDR, thereby activating this receptor and regulating gene transcription \[[@ref003]\].

The VDR and the enzyme 1a-hydroxylase are also expressed in other tissues, including neuronal and glial cells \[[@ref001]\]. There is evidence that vitamin D has a neuroprotective effect on brain function. Firstly, 1,25-(OH)~2~D inhibits the synthesis of inducible nitric oxide synthase (iNOS), which catalyzes nitric oxide, a free radical that can damage cells \[[@ref004]\]. Secondly, 1,25-(OH)~2~D stimulates *γ*-glutamyl transpeptidase activity. The enzyme *γ*-glutamyl transpeptidase is important in the synthesis of glutathione. Glutathione is an antioxidant that neutralizes free radicals and in this way protects cells from damage \[[@ref004]\]. In addition, vitamin D may act as a neurotrophic factor. Neveu et al. showed that vitamin D stimulates brain cells to produce several growth factors, like nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF) and neurotrophin 3 (NT3) \[[@ref005]\]. These neutrophic and neuroprotective actions of vitamin D suggest that this vitamin can stimulate the protection and growth of neuronal cells. Therefore, vitamin D may slow down the progression of neurodegenerative diseases, such as PD.

OBJECTIVE {#sec0010}
=========

The aim of this study was to investigate the evidence for a relationship between vitamin D and PD by summarizing observational and interventional studies in humans, as well as relevant experimental studies.

METHODS {#sec0015}
=======

A literature search was performed in Medline, Embase and Cochrane Library databases from inception until March 2014. The following (MESH) terms were used: 'Vitamin D' OR cholecalciferol OR 'ergocalciferol' AND 'Neurodegenerative Diseases' OR 'Parkinson' OR 'Huntington' OR 'dementia' OR 'ALS' OR 'lewy body' OR 'multiple system atrophy'.

Excluded were articles not in the English language and studies not investigating PD or vitamin D.

All identified titles (*n* = 5184) were independently evaluated by two reviewers. First, a search within the neurodegenerative diseases revealed that, contrary to our expectations, more studies were found that addressed vitamin D than PD. We selected only those studies that were related to both PD and vitamin D (i.e. correlation studies, case-control and interventional studies in humans, and experimental studies) that examined the relationship between vitamin D and PD. This yielded 107 studies on PD, of which 75 were excluded based on the abstract alone, because vitamin D or PD was not investigated. After scrutinizing the remaining 32 articles 12 articles were excluded because: i) vitamin D levels, vitamin D supplementation or vitamin D intake were not reported, ii) PD was not established, and iii) the article was not in the English language. Finally, 20 studies were included in the present review. [Figure 1](#jpd-6-jpd150615-g001){ref-type="fig"} shows the inclusion process of the studies.

RevMan 5 was used to perform a meta-analysis and create forest plots.

RESULTS {#sec0020}
=======

Serum 25(OH)D concentration in PD vs. healthy controls: Observational studies {#sec0025}
-----------------------------------------------------------------------------

[Table 1](#jpd-6-jpd150615-t001){ref-type="table"} lists the eight studies in which vitamin D status was compared between patients with PD and a healthy control group \[[@ref008]\]. With the exception of one study \[[@ref014]\], all showed that serum 25(OH)D in patients is significantly lower than in healthy controls. Our meta-analysis ([Table 2](#jpd-6-jpd150615-t002){ref-type="table"}) confirmed this relationship with a significant mean difference of 11.6 ug/ml (SD 12.2--10.9) in the PD group as compared with the healthy controls. Of these eight studies, only six were included in the meta-analysis \[[@ref009]\] because two studies did not report the standard deviation of the level of vitamin D \[[@ref008]\]. However, these two latter studies were in line with the results of the meta-analysis and showed a significantly higher vitamin D level in the control group compared with patients with PD \[[@ref008]\]. Sato et al. made a separate analysis of vitamin D status in patients with Hoehn & Yahr (H&Y) stage 1--2 and with stage 3--5 \[[@ref009]\]; serum 25(OH)D was lower in the group with H&Y stage 3--5 compared with patients with stage 1--2 \[[@ref009]\]. Our meta-analysis included the group with H&Y stage 3--5; however, when including only results from the group with H&Y stage 1--2, mean serum 25(OH)D level in patients with PD was still lower (10.72 ug/m; --11.49--9.95) than in healthy controls.

Serum 25(OH)D concentration and relation with balance in PD: Observational study {#sec0030}
--------------------------------------------------------------------------------

Peterson et al. investigated the relationship between serum 25(OH) D level and balance in a cross-sectional, observational pilot study including 40 patients with PD. Balance was examined using five tests: the motor control test, sensory organization test, sit and stand test, walk and turn test, and the unilateral stance eyes open and closed test. The authors found a significant positive correlation between serum 25(OH)D and automatic postural responses \[[@ref016]\].

Vitamin D intake/exposure and PD: Observational studies {#sec0035}
-------------------------------------------------------

Miyake et al. studied the ingestion of vitamin D and the risk of PD; no significantly lower vitamin D intake was found in patients versus controls\[[@ref017]\].

Relationship between VDR polymorphisms and PD: Observational studies {#sec0040}
--------------------------------------------------------------------

Five observational studies investigated VDR polymorphisms in PD \[[@ref016]\]. Four compared VDR polymorphism in PD with healthy controls ([Table 3](#jpd-6-jpd150615-t003){ref-type="table"}) \[[@ref016]\]. Several genetic variants of the VDR were examined ([Table 3](#jpd-6-jpd150615-t003){ref-type="table"}). In two studies a significant association was found between the rs10735810 (*Fok*I) C allele and PD, with a higher frequency of the C allele in PD compared to controls \[[@ref019]\]. In contrast, Suzuki et al. found that the VDR variant *Fok*I CC was associated with milder forms of PD in a Japanese population \[[@ref021]\].

Vitamin D supplementation in PD: Interventional studies {#sec0045}
-------------------------------------------------------

Suzuki et al. evaluated the effect of vitamin D supplementation on disease progression in PD \[[@ref022]\]. In a double-blind, placebo-controlled trial among 104 patients with PD during 12 months, 56 received 1200 IU vitamin D per day and 58 received placebo. Primary outcome was the percentage worsening on the modified H&Y scale and the Unified Parkinson Disease Rating Scale (UPDRS). The authors found that worsening of the H&Y and the UPDRS part II was significantly less in the vitamin D supplementation group \[H&Y: RR 2.37 (95% CI: 1.06--5.31) *p* = 0.028\], \[UPDRS part II: RR 1.68 (95% CI 1.68 (1.02--2.78) *p* = 0.036)\]. Interaction analyses showed that the VDR genotype rs10735810 (*Fok*I) modified the effect of vitamin D. Patients with the *Fok*I TT allele had a significant and consistent response to vitamin D supplementation whereas individuals with VDR *Fok*I CT had a moderate response. However, patients with *Fok*I CC showed no significant effect of vitamin D supplementation compared to placebo. None of the other VDR variants \[rs1544410 (*Bsm*I), rs731236 (*Taq*I) rs7975232 (*Apa*I), rs11568820 (*Cdx2*)\] influenced the effect of vitamin D.

Vitamin D supplementation in rodents {#sec0050}
------------------------------------

Five studies in animal models of PD investigated the effect of vitamin D therapy on substantia nigra dopamine neurons after 6-OHDA or MPTP lesion ([Table 4](#jpd-6-jpd150615-t004){ref-type="table"}) \[[@ref023]\]. One study showed a significantly higher dopamine level and two a significantly higher concentration of the enzyme promoting conversion to dopamine, tyrosine hydroxylase (TH), in the substantia nigra of the vitamin D supplemented rodent group \[[@ref025]\]. One of these studies also demonstrated that oxidative injury of the substantia nigra was significantly lower after vitamin D supplementation \[[@ref025]\]; this result was in line with another study reporting higher neuronal survival in the substantia nigra when 1,25(OH)~2~D was injected \[[@ref023]\]. However, very high concentrations of 1,25(OH)~2~D enhanced neurotoxity, as also found in Klotho-insufficient mice that resemble human aging and exhibit abnormal levels of serum 1,25-(OH)~2~D caused by abnormally high vitamin D metabolism in the kidney \[[@ref023]\]. On the other hand, Kaluef et al. showed significantly impaired motor function in mice that totally lacked the vitamin D receptor \[[@ref029]\].

DISCUSSION {#sec0055}
==========

To our knowledge, this is the first systematic review to focus on the relationship between vitamin D and PD: 20 studies (14 observational, 1 interventional and 5 rodent studies) were examined. In almost all human studies, patients with PD had lower serum 25(OH)D levels than controls \[[@ref008]\] and higher 25(OH)D levels were associated with better motor function \[[@ref008]\]. Furthermore, higher 25(OH)D levels were associated with a lower risk of PD in humans \[[@ref008]\] and with neuroprotection in rodent models of PD \[[@ref023]\].

Our meta-analysis revealed that the average serum 25(OH)D level in patients with PD was 11.6 ug/ml (SD 12.2-10.9) lower than in healthy controls. The absence of a correlation between vitamin D status and PD in one study \[[@ref014]\] may have been because the 25(OH)D levels of the control group were measured in winter whereas the patients were measured in summer. The high prevalence of vitamin D deficiency in PD may be a consequence of reduced outdoor activity and, therefore, less sun exposure due to limited mobility. The case-control study of Peterson et al. showed that higher serum 25(OH) D was related to better automatic postural responses in PD \[[@ref016]\], whereas in a clinical trial vitamin D supplementation with 1200 IU vitamin D prevented worsening on the H&Y and UPDRS scales \[[@ref022]\]. In addition to a symptomatic effect on motor function, vitamin D may have neurotrophic or neuroprotective effects in PD. All rodent studies showed a beneficial effect of vitamin D on the degree of toxin-induced loss of dopamine neurons, with the exception of excessively high vitamin D levels or an abnormally high activation of vitamin D in Klotho mice that enhanced neurotoxic effects \[[@ref023]\]. These latter findings are in line with results from human studies in which extremely high doses of vitamin D were shown to enhance fractures \[[@ref030]\]. An important consideration is that the toxin-induced dopamine neuron loss in rodent models of PD is different from the much slower injury to the substantia nigra in PD.

Genetic studies indicated a possible relation between PD and the VDR polymorphism *Fok*I, The *Fok*I 'CC' allele has been associated with milder forms of PD, possibly due to a higher and more efficient functionality of this VDR allele variant. This is in line with results of other studies investigating the *FokI* polymorphisms \[[@ref031]\]. Indeed, patients with a *Fok*I 'T' allele and (presumably) less functionality, were more responsive to vitamin D supplementation \[[@ref022]\]. However, the results remain contradictory because two studies showed a small but significantly higher frequency of the VDR variant '*Fok*I C' allele in PD and suggest the opposite, i.e. a possible higher risk for PD in the presence of a *Fok*I C allele \[[@ref019]\]. More studies are needed to confirm and elucidate the relationship between *Fok*I VDR polymorphisms and PD.

A strength of the present study is that it provides a broad view on what is known about the relationship between vitamin D and PD. Limitations include the possibility of publication bias, differences between the patient populations, and variations in the applied methodology (e.g. variations in study population, vitamin D supplementation, and outcome measures).

In conclusion, this systematic review indicates that PD is associated with lower serum vitamin D levels \[[@ref008]\]. Secondly, higher vitamin D levels are associated with better balance, and vitamin D supplementation appears to have a positive effect on PD motor symptoms \[[@ref016]\]. Finally, results from rodent models suggest that vitamin D may also have a neuroprotective effect \[[@ref023]\]. Additional studies are needed to further explore and elucidate the symptomatic and potential neuroprotective effects of vitamin D in Parkinson's disease.
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###### 

Levels of serum 25(OH)D in patients with Parkinson's disease and in healthy controls

  Author                                  Patients                                    H&Y            Serum level 25(OH) D             *p*-value PD vs controls
  --------------------------------------- -------------------------------- ------------------------- ------------------------------- --------------------------
  Sato et al. 1997 \[[@ref009]\]          20 PD H&Y 1-2                            1-2,3--5          PD H&Y 1-2 : 21.7 (8.5) ng/ml     H&Y 3--5 *P* \<  0.001
                                          51 PD H&Y 3--5                                             PD H&Y 3--5 : 8.9(3.2) ng/ml       H&Y 1-2 *P* \>  0.05
                                          33 controls                                                controls: 21.6 (3.1) ng/ml      
  Sato et al. 2005 \[[@ref015]\]          142 PD                                   3.3 (1.1)         PD: 11.0 (3.2) ng/ml                  *P* \<  0.001
                                          99 controls                                                controls: 33.3 (3.1) ng/ml      
  Abou- Raya et al. 2009 \[[@ref010]\]    82 PD                                    3.0 (0.5)         PD 12.9 (9.9) ng/ml                    *p* = 0.001
                                          68 controls                                                controls: 21.6 (4.8) ng/ml      
  Topal et al. 2010 \[[@ref008]\]         48 PD patients and 50 controls         Not reported        PD 27.5 ng/ml                          *P* \<  0.01
                                                                                                     controls: 33.8 ng/ ml           
  Evatt et al. 2011 \[[@ref011]\]         97 PD,                            1.7 (0.5) \[[@ref001]\]  PD: 31.9 (13.6) ng/mL,                  *P* = 0.03
                                          (97 AD patients)                                           controls: 37.0 (14.5) ng/ml     
                                          99 controls                                                                                
  Senel et al. 2011 \[[@ref012]\]         19 PD patients                         Not reported        PD:12.63 ng/ml                         *P* \<  0.01
                                          20 controls                                                controls: 20.42 ng/ml           
  Van den Bos et al. 2013 \[[@ref013]\]   186 PD                                     \<2.5           pd: 19.3 (8.1) ng/ml                  *P* \<  0.000
                                          802 controls                                               controls: 22.7 (9.2) ng/ml      
  Petersen et al. 2014 \[[@ref014]\]      80 PD                                    2.6 (1.3)         PD 15.7 (9.6) ng/ml                     *P* = 0.49
                                          154 controls                                               controls: 16.4 (9.9) ng/ml      

PD = Parkinson's disease; H&Y = Hoehn and Yahr rating scale.

###### 

Meta-analysis of serum 25(OH)D levels in patients with Parkinson's disease and in healthy controls

                                                                         PD    Control   Mean Difference   Mean Difference                                                               
  -------------------------------------------------------------------- ------ --------- ----------------- ----------------- ------ ------ -------- ------------------------------ ------ --
  Sato 1997 H&Y 3--5 ~ \[9\] ~                                          8.9      3.2           51               21.6         3.1     33    24.8%    --12.70 \[--14.07, --11.33\]   1997  
  Sato 2005 ^\[15\] ^                                                   11.9     6.5           142              33.3         3.1     99    30.9%    --21.40 \[--22.63, --20.17\]   2005  
  Abou-Raya 2009 ^\[10\] ^                                              12.9     9.9           82               21.6         4.8     68     7.9%     --8.70 \[--11.13, --6.27\]    2009  
  Evatt 2011 ^\[11\] ^                                                  31.9    13.6           97                37          14.5    99     3.0%     --5.10 \[--9.03, --1.17\]     2011  
  Van des Bos 2013 ^\[13\] ^                                            19.3     8.1           186              22.7         9.2    802    26.6%     --3.40 \[--4.73, --2.07\]     2012  
  Peterson 2014 ^\[14\] ^                                               15.7     9.6           80               16.4         9.9    154     6.8%      --0.70 \[--3.32, 1.92\]      2014  
  Total(95% CI)                                                                                638                                  1255   100.0%   --11.55 \[--12.23, --10.86\]         
  Hetergeneity: Chi^2^ = 474.94, df = 5(*P* \<  0.00001); I^2^ = 99%                                                                                                                     
  Test for overall effect: Z = 33.09(*P* \<  0.00001)                                                                                                                                    

H&Y = Hoehn and Yahr.

###### 

Vitamin D receptor polymorphisms in patients with Parkinson's disease (PD) and a healthy control group

  Authors                                 Ethnicity     Study population   Mean age (years)      H&Y                UPDRS              Genetic variants VDR
  ------------------------------------ --------------- ------------------ ------------------ ----------- ---------------------------- ----------------------
  Han et al. 2012 \[[@ref021]\]          Chinese Han         PD 260           70.9 ±6.1        2(1--4)    UPDRS part III: 15 (3--36)    rs10735810 (FokI)
                                                          controls 282        69.4 ±9.7                                                  rs1544410 (BsmI)
  Török et al. 2013 \[[@ref020]\]         Hungarian          PD 100            66.4±9.3          N.A                 N.A                rs10735810 (FokI)
                                                          controls 109         64.0±8.2                                                  rs1544410 (BsmI)
                                                                                                                                         rs731236 (TaqI)
                                                                                                                                         rs7975232 (ApaI)
  Lin et al. 2014 \[[@ref018]\]                                                                                                       
                                          Taiwanese          PD 700           68.7±11.2          N.A                 N.A                    rs2853559
                                                          controls 792           N.A                                                        rs4334098
                                                                                                                                            rs7299460
                                                                                                                                            rs7968585
                                                                                                                                            rs7976091
                                                                                                                                            rs10083198
  Peterson et al. 2014 \[[@ref014]\]    Farao Islands        PD 121            74.5±9.9       2.6 (1.3)              N.A                 rs7975232 (ApaI)
                                                          Conrols 235          75.0±9.9                                                  rs1544410 (BsmI)
                                                                                                                                         rs731236 (TaqI)

^\*^*P* \<  0.05. H&Y = Hoehn and Yahr rating scale; UPDRS = unified Parkinson's disease rating scale. N.A. = not applicable; VDR = vitamin D receptor.

###### 

Data on vitamin D supplementation in rodents

  Authors                             Rodent group
  ----------------------------------- ---------------------------
  Shinpo et al. 2000 \[[@ref023]\]    Not available
                                      
                                      
                                      
                                      
                                      
  Wang et al. 2001 \[[@ref027]\]      16 vitamin D supplemented
                                      16 controls
                                      
                                      
  Lin et al. 2003 \[[@ref025]\]       6 vitamin D supplemented
                                      6 controls
  Sanchez et al. 2009 \[[@ref024]\]   
  TH                                  
                                      40 group 1
                                      40 group 2
                                      40 group 3
                                      40 group 4
  Dean et al. 2012 \[[@ref026]\]      4 vitamin D depleted
                                      4 controls
                                      
                                      
                                      
                                      

^\*^*P* \<  0.01; ^\*\*^ *P* \<  0.05 SN = substabtia nigra GNDF = glial cell line-derived neurotrophic factor TH = tyrosine hydroxylase MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine BSO: DL-buthionine-S,R-sulfoximine MPP+: 1-methyl-4-phenylpyridinium 6-OHD: 6-hydroxydopamine.
